Ships within 24 hours
Independent US-lab tested
5X full-panel testing
Discreet packaging
Mixed, bottled & tested in the USA
Free shipping over $200
COA with every peptide
NAD+ lab results

Lot 06-2606

NAD+

One bulk lot, independently tested by ILS Laboratories at each vial size (2 certificates). Latest analysis 04/16/2026.

NAD+ 500mg lot 06-2606 certificate of analysisPDFView full PDF

Signed certificate

The full ILS Laboratories certificate for NAD+ 500mg, lot 06-2606. Click the preview to open the signed PDF, or read the same results rendered below.

ILS Laboratories

8222 Vickers St, Suite 106, San Diego, CA 92111

(619) 329-3999 · ils-lab.com

Certificate of Analysis

PASS

NAD+ — 500mg

Independently tested for: Peerless Peptides

COA #
COA-2026-412997
Method
Full QC Panel
Lot Number
06-2606
Analysis Date
04/16/2026
Concentration
500mg
Appearance
good
Received
03/20/2026
Volume
3mL

Identity

NAD+

Purity

99.08%

Full QC Panel

AnalyteSpecificationResultUnitStatus
Purity (HPLC)≥ 95.0%%99.08%%PASS
Net Peptide ContentReport Only520.17mgN/A
Identity (ID)NAD+Confirmed—PASS
Sterility (PCR)No GrowthNo GrowthppmPASS
Endotoxin (USP <85>)< 0.05 EU/mL≤ 0.05 EU/mLEU/mLPASS

Date Tested: 04/16/2026· HPLC at UV 214 nm.

HPLC Chromatogram

HPLC chromatogram for NAD+ lot 06-2606

Heavy Metals Analysis (ICP-MS)

TestSpecificationResultStatus
Arsenic (As)≤ 1.5Not DetectedPASS
Cadmium (Cd)≤ 0.5Not DetectedPASS
Lead (Pb)≤ 1.0Not DetectedPASS
Mercury (Hg)≤ 1.5Not DetectedPASS
Chromium (Cr)≤ 10.0Not DetectedPASS

Elemental impurities analyzed by Inductively Coupled Plasma Mass Spectrometry (ICP-MS) per USP <233> methodology.

Notes & Methodology

  • The sample was confirmed to be NAD+ by HPLC. Identification by chromatographic retention time comparison with a reference standard.
  • Elemental impurities analyzed by ICP-MS per USP <233> methodology. Acceptance criteria are internal laboratory quality screening limits for research-use materials and do not represent evaluation against any specific pharmacopoeial monograph or product specification.
  • Endotoxin tested per USP <85> kinetic chromogenic method. Acceptance criteria per client specification.
  • Sterility testing performed by PCR (Polymerase Chain Reaction) method.
  • Peptide purity determined by RP-HPLC area normalization at 214 nm. Value represents the percentage of the target peptide relative to all peptide-related peaks. Non-peptide process-related impurities, if detected, are excluded from the calculation.
  • Accreditation Scope: ILS Laboratories maintains ISO/IEC 17025 accreditation for activities listed in its published PJLA scope. Peptide testing reported on this certificate is performed for Research Use Only.
  • This certificate reports analytical results for the sample(s) submitted to ILS Laboratories for testing. All sample identifications, product names, brand names, lot/batch numbers, and labeled content are provided by the submitting party and have not been independently verified. Results reflect only the analytical testing of the specific sample(s) provided and do not constitute an evaluation or endorsement of the manufacturer's processes, quality systems, or overall production. ILS Laboratories makes no representations regarding the intended use, safety, efficacy, regulatory status, or intellectual property ownership of any materials tested.

Reproduced from the certificate issued by ILS Laboratories. The full signed document is linked below.

Dr. Greg Kalyuzhny

Lab Director

ILS Laboratories

ISO/IEC 17025 accredited laboratory (PJLA), using validated analytical methods

Verify with the laboratory

portal.ils-lab.com/verify/412997

Opens the record held by ILS Laboratories, independently of this page.

Test History for NAD+

Across 1 batch: 99.38% average purity · range 99.08% to 99.67%

Batch 06-2606

04/16/2026

99.08-99.67%Endo PASS
Current